Tue.Oct 29, 2024

article thumbnail

With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end

Fierce Pharma

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. | Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.

Sales 302
article thumbnail

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

MedCity News

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study.

Biopharma 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pfizer bumps up revenue outlook by $1.5B in Paxlovid rebound amid criticism from activist investor Starboard

Fierce Pharma

Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | The company is projecting yearly sales of $61 billion to $64 billion in a $1.5 billion boost from previous forecasts.

Sales 299
article thumbnail

Are You a Startup Looking for an Audience of Investors? We Have The Perfect Pitch Contest for You!

MedCity News

As companies begin to make plans for 2025, add the INVEST Pitch Perfect Contest to your calendar. The post Are You a Startup Looking for an Audience of Investors? We Have The Perfect Pitch Contest for You! appeared first on MedCity News.

Biopharma 119
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Bristol Myers partner Zai Lab plots KarXT filing in China after trial win

Fierce Pharma

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers Squibb and its partners are moving fast to expand the global reach of th | In a phase 3 bridging study run by Zai Lab in China, Bristol Myers Squibb's KarXT helped schizophrenia patients chart a 9.2-point total-score reduction on the Positive and Negative Syndrome Scale versus placebo at week 5, teeing up a forthcoming regulatory filing.

FDA 277
article thumbnail

NHS funding boost confirmed ahead of tomorrow's Budget

pharmaphorum

UK government confirms £1.8bn funding boost to NHS to cut waiting lists, including £1.

More Trending

article thumbnail

PHTI review of digital hypertension tools gives mixed results

pharmaphorum

An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking.On the plus side, the health technology assessment (HTA) body has concluded that tools to help people manage their antihypertensive drug treatment can deliver benefits in reduced blood pressure.

article thumbnail

Novartis' Pluvicto enters FDA orbit for expansion bid as agency requests 'flexibility'

Fierce Pharma

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key application in an earlier treatment setting of prostate cancer. The company made the decision in response to the FDA's request for "flexibility" in its review timeline, Novartis CEO Vas Narasimhan explained.

FDA 299
article thumbnail

Pfizer rebuffs Starboard criticism as it raises forecasts

pharmaphorum

Pfizer CEO Albert Bourla hit back at activist investor Starboard Value, saying measures to reset the pharma group are already well in hand

Pharma 106
article thumbnail

Protega scores FDA nod for new dosage of abuse-deterrent opioid Roxybond

Fierce Pharma

The FDA has approved the first abuse-deterrent, immediate-release, 10 mg opioid tablet for pain management. The drug, Roxybond, has been approved in other dosages.

FDA 261
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

pharmaphorum

AbbVie agrees a $1.4bn cash deal to acquire Aliada Therapeutics, adding another anti-amyloid antibody to its Alzheimer's pipeline.

105
105
article thumbnail

Drug pricing and the 2024 presidential election

Fierce Pharma

As the 2024 U.S. | This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

246
246
article thumbnail

WHO Activates Global Health Emergency Corp in Response to Mpox

PharmaTech

WHO and its partners are providing support to countries dealing with mpox outbreaks.

105
105
article thumbnail

EC approves AstraZeneca’s Fasenra for EGPA treatment

Pharmaceutical Technology

The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.

105
105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Joy as NICE lifts restrictions on myeloma drug Elrexfio

pharmaphorum

Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.In June, the cost-effectiveness agency cleared the use of the BCMAxCD3 bispecific antibody with 'optimised guidance' that allowed it to be used for a narrower range of patients than was covered by the approved label for the drug.

Patients 105
article thumbnail

Next-gen Virtual Tools for Education & Learning in the Life Sciences

Impetus Digital

Pharma-exclusive Webinar: Next-gen Virtual Tools for Education & Learning in the Life Sciences About the webinar Join us for one of three webinar sessions, tailored exclusively for Pharma leaders. Between November 18–20, we will delve into the future of educational tools in the life sciences industry. Our expert speakers will unveil the latest virtual tools that are reshaping how professionals engage with and educate HCPs, patients, and internal teams.

Education 104
article thumbnail

Novartis pays $150m upfront for Monte Rosa degrader drug

pharmaphorum

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1-directed molecular glue degrader programme.

Pharma 69
article thumbnail

Do Healthcare Providers Really Want to Go Back to In-person Meetings?

Impetus Digital

A version of this article was previously published on PharmaPhorum. It is easy to assume that healthcare providers (HCPs) all want to go back to in-person meetings after having been confined to Zoom and Microsoft Teams meetings during the pandemic years. Anecdotally, however, we heard different things: many HCPs highlighted the convenience of the virtual format and considered this a silver lining from the long months of social and physical distancing.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

A journey from personal to public: Digital health passports today

pharmaphorum

A digital health passport is an app, or online certification, that displays a traveller’s health or vaccination record. It can save lives, on both private and public levels. In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Matt Hollingsworth, co-founder and CEO of Carta Healthcare, a company seeking to support the healthcare data registry market by transforming a previously manual clinical data abstraction process.

article thumbnail

AbbVie agrees $1.4 billion Alzheimer’s acquisition

European Pharmaceutical Review

AbbVie has signed to acquire the biotech Aliada Therapeutics for $1.4 billion. The deal enables the advancement of a potentially best-in-class disease-modifying therapy for Alzheimer’s. Dr Roopal Thakkar , Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie, highlighted that neuroscience is one of AbbVie’s key growth areas.

article thumbnail

STRIPE Names Recipients of the Inaugural Double Helix Awards

Pharmacy Times

The STRIPE Double Helix Awards celebrate individuals and organizations that have made exceptional contributions to the field of pharmacogenomics.

59
article thumbnail

Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial

Pharmaceutical Technology

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years of age.

59
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Pharma Pulse 10/29/24: Strengthening Regulatory Framework for Compounded Medications, Cancer Disparities in Rural Areas & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 59
article thumbnail

How AZ’s respiratory wins are ramping up for a bigger prize in COPD

PharmaVoice

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.

59
article thumbnail

South Korean pricing reform suggests more flexible drug reimbursement negotiations

Pharmaceutical Technology

South Korea’s Ministry of Health and Welfare recently disclosed its proposal to revise the drug reimbursement and price-setting regulations.

article thumbnail

Researchers Begin Phase 3 Trial Assessing Adjuvant V940 With Pembrolizumab to Treat Non–Small Cell Lung Cancer

Pharmacy Times

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Focusing on Solid Dosage Trends and Demand

PharmaTech

Webinar Date/Time: Fri, Nov 22, 2024 11:00 AM EST

52
article thumbnail

American Pharmacists Month: Stephanie Y. Crawford, PhD, MPH, on Mentorship, Health Equity, and the Expanding Role of Pharmacists

Pharmacy Times

Stephanie Y. Crawford, PhD, MPH, highlights the expanded roles of pharmacists in clinical and non-clinical settings and their increased role in patient care, sharing personal experiences where pharmacists have been instrumental in supporting her family's health needs.

article thumbnail

Pharma Advertising Strategies for Effective Brand Engagement

Pharma Marketing Network

Pharma advertising isn’t just about promoting products—it’s about reaching patients, caregivers, and healthcare professionals with valuable, meaningful information. With digital channels, evolving regulations, and changing patient expectations, creating an impactful advertising strategy can feel complex. In this article, we’ll explore key pharma advertising strategies that resonate with your audience, enhance brand engagement, and help you stay ahead in a competitive industry.

Pharma 52
article thumbnail

BIO 2024: CDMOs Focus on Complex Technical Challenges to Boost Startup Biotechs

PharmaTech

Marianna Tcherpakov, PhD, director of Business Development, CMC Services, at Frontage Laboratories, spoke on the CDMO’s role in tackling complex technical challenges to enable startup biotechs solve scale up problems.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A